Psychedelic Combination Therapy Balancing Neuroplasticity and Hallucinations

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for chronic schizophrenia, particularly those with negative symptoms, are limited, and existing antipsychotic drugs face challenges in managing hallucinogenic effects while providing neuroplasticity benefits.

Innovation Solution

Combining psychedelic drugs like psilocybin with antipsychotics possessing 5-HT2A antagonist properties, such as clozapine, and optionally with NMDA receptor agonists like D-serine, to modulate 5-HT2A and NMDA receptor functions, preventing positive symptoms and enhancing neuroplasticity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If psychedelic drugs are used to induce neuroplastic changes, then neuroplasticity is enhanced, but hallucinogenic effects and positive symptoms are induced

Engineering Contradiction:

Improveneuroplasticity enhancementVSAvoidhallucinogenic effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent uses 5-HT2A receptor antagonists as intermediary substances that block the hallucinogenic pathway while allowing the neuroplasticity-enhancing pathway to proceed. The antagonist acts as a mediator that separates the beneficial neuroplastic effects from the harmful hallucinogenic effects by selectively interfering with receptor binding in a controlled manner.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the pharmacological parameters by combining psychedelics with 5-HT2A receptor antagonists, altering the receptor activation profile. This parameter change allows the system to achieve neuroplasticity enhancement without the full hallucinogenic effect, as the antagonist modulates the receptor response to the psychedelic compound.

Inventive Principle:

Principle #35Parameter changes

2Object-generated harmful factors

If antipsychotic drugs block 5-HT2A receptors to prevent positive symptoms, then hallucinogenic effects are reduced, but neuroplasticity benefits are limited

Engineering Contradiction:

Improvepositive symptomsVSAvoidneuroplasticity enhancement

Core Design Contradiction:

Object-generated harmful factorsVSReliability

Solution Approach 1:

The patent applies partial blocking of 5-HT2A receptors rather than complete blockade. By using sub-maximal doses of 5-HT2A receptor antagonists in combination with psychedelics, the system achieves partial receptor occupancy that is sufficient to reduce positive symptoms but not so high as to completely prevent neuroplasticity enhancement.

Inventive Principle:

Principle #16Partial or excessive action

Solution Approach 2:

The patent merges two opposing pharmacological actions - psychedelic-induced 5-HT2A receptor activation (for neuroplasticity) and antagonist-mediated blocking (for symptom reduction). This combination therapy integrates both mechanisms to achieve a balanced therapeutic effect that addresses both neuroplasticity and symptom management.

Inventive Principle:

Principle #5Merging (Combining)

3Reliability

If combination therapy is used to prevent positive symptoms while enhancing neuroplasticity, then treatment effectiveness is improved, but treatment complexity increases

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtreatment regimen

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent creates a multi-functional treatment regimen where the combination of psychedelic and 5-HT2A receptor antagonist simultaneously achieves multiple therapeutic goals: enhancing neuroplasticity, reducing positive symptoms, and preventing hallucinogenic effects. This universal approach addresses multiple aspects of schizophrenia treatment within a single therapeutic protocol.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This combination effectively reduces negative symptoms and enhances neuroplasticity, offering superior clinical improvements over existing treatments for chronic schizophrenia, depression, and PTSD.

Implementation Method 1

Classical tryptaminergic psychedelics bind with high affinity to 5-HT2A receptors

Methodology Applied

Scientific EffectReceptor binding:

Implementation Method 2

the action of clozapine to block 5-HT2A receptors

Methodology Applied

Scientific EffectReceptor blockade:

Implementation Method 3

D-serine acts as a co-agonist at the glycine modulatory site of N-methyl-D-aspartate type (NMDA) glutamate receptors (NMDAR)

Methodology Applied

Scientific EffectCo-agonism:

Data Source

PatentUS20260083759A1Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders

Publication Date: 2026.03.26 HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD

AI summary

This invention provides in some aspects, combinations, compositions and kits comprising a psychedelic drug and an NMD A receptor agonist and applications and uses of same for treating, reducing the incidence of, reducing the severity of or improving a pathology of a subject with a neurologic disease or disorder, a neurocognitive disease or disorder, or a motor disease or disorder, or for enhancing neuroplasticity in a subject with a neurologic disease or disorder, a neurocognitive disease or disorder, or a motor disease or disorder making use of the combinations, compositions and kits of this invention.